Project Grant W81XWH2210762
Award Date
9/15/22
Completion Date
9/14/25
Dollars Obligated
$5.5M
Federal Agency
Medical Command
Awardee
Carogen Corp (JNMNVKEUU2Y3)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06518, USA
Similar Awards
This federal Project Grant award, in the amount of $629,992.00, was issued on September 1, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant funding supports Carogen Corp, a minority-owned biopharmaceutical company based in Hamden, Connecticut, to test the safety and efficacy of CARG-201, an RNA replicon-based therapeutic vaccine for the treatment of chronic hepatitis B virus. The research project aims to advance innovative...
The federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,480,488 to Brigham & Women's Hospital Inc. to research the combination of mRNA nanotherapy with standard antiangiogenic/immunotherapy for hepatocellular carcinoma (HCC). The research project runs from September 1, 2023 to August 31, 2026. As part of this effort, Massachusetts General Hospital will conduct preclinical studies to evaluate the...
The Department of the Army Medical Command awarded Invvax, Inc. a $1,878,970 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research titled "Invariance Mapping of the Complete HBV Genome and Testing of MRE11 Repair Nuclease Toward the Improvement of CRISPR/Cas Therapy for Hepatitis B." The period of performance is from September 1, 2022 to August 31, 2026. Under this award, Invvax will conduct research to map the complete genome of...
This $1,134,777 four-year Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) will fund in vivo mechanistic characterization of the angiogenic immune checkpoint in liver cancer at The Johns Hopkins University. The research aims to transform healthcare for Service Members, Veterans, and the American public through innovative biomedical research. The award will support basic, applied, and advanced studies investigating potential...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The Department of the Army Medical Command awarded Yale University a $1,004,997 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund Yale University's pilot development of new forms of chimeric antigen receptor therapies for kidney cancer from August 15, 2021 to August 14, 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...
The Defense Health Agency awarded Yale University a $3,129,087.00 Project Grant on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced research to develop integrative platforms for cellular immunotherapies against resistant hematopoietic malignancies and solid tumors. Key aims include targeting combinations of gene editing and CAT inhibition to enhance CAR-T cell function, and investigating gene editing coupled with CAT...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,683 to the Dana-Farber Cancer Institute in Boston, MA to conduct research aimed at enhancing immune checkpoint blockade responsiveness and tertiary lymphoid structure formation through CD4+TFHx13 CAR-T cells to achieve cures for clear cell renal cell carcinoma (CCRCC). The research will involve experimental design and computational analysis of...
The Department of the Army Medical Command awarded a $695,089 Project Grant to the Dana-Farber Cancer Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 1, 2022 to May 31, 2025 to develop noninvasive diagnosis of immune checkpoint inhibitor-associated myocarditis. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...